Chemours Q2 2026 Earnings Preview: Analysts Forecast Profitability Turnaround

• Chemours is expected to report Q2 2026 earnings on August 4, with analysts forecasting a significant recovery to approximately $0.496 per share.
• Institutional investors have aggressively accumulated shares in Q1, signaling strong conviction despite recent stock volatility and operational headwinds.
• The Thermal & Specialized Solutions segment drove Q1 growth, while the company faces risks from disruptions at the Washington Works facility.
• Management forecasts a full-year 2026 EPS of $1.36, citing regulatory tailwinds for refrigerants as a key structural driver for profitability.

Chemours Co (NYSE: CC) is scheduled to announce its second-quarter 2026 financial results after the market closes on Tuesday, August 4, 2026. The subsequent earnings call will take place on Wednesday, August 5, at 8:00 a.m. ET . Market consensus anticipates a robust turnaround for the specialty chemicals company, with analysts projecting earnings per share of $0.4964 and revenue of $1.6545 billion for the quarter . This represents a substantial acceleration from the first quarter, where Chemours reported a modest EPS of $0.05 .

The stock currently trades around $16.86, well below its consensus analyst price target of $24.10. This valuation gap suggests that the market hasn't fully priced in the anticipated earnings rebound. Recent institutional activity reinforces this sentiment, with broad-based buying from diverse funds indicating a structural re-rating or bottom-fishing behavior among sophisticated capital . Notably, Healthcare of Ontario Pension Plan Trust Fund increased its stake by over 5,500% in the first quarter, while other major funds like Baird Financial and Royal Bank of Canada also initiated or increased positions .

What Drives the Expected Q2 Earnings Recovery?

The projected earnings recovery is underpinned by improved operational performance and favorable market conditions . In the first quarter, the Thermal & Specialized Solutions segment drove positive results, delivering 22% year-over-year sales growth. This growth was bolstered by continued strength in refrigerants, supported by regulatory tailwinds favoring lower-global-warming-potential alternatives . The Zacks Earnings ESP model suggests a high likelihood of a positive earnings beat, with analysts having recently revised their views more bullish.

However, the company's performance has been mixed across segments. The Advanced Performance Materials segment faced headwinds from operational disruptions at its Washington Works facility, which impacted production efficiency and margins . These disruptions contributed to a 13% stock decline following the Q1 earnings release, despite the EPS beat . Investors are weighing the sustainability of the turnaround against these operational risks .

How Does the Full-Year Outlook Compare to Prior Performance?

Looking ahead, management has set a full-year 2026 EPS forecast of $1.36 . This represents a significant improvement from the prior year's loss of $2.80 per share . For the second quarter of 2026, adjusted EBITDA guidance is set between $220 million and $250 million . The average analyst expectation for the current fiscal year is $1.00 to $1.18 EPS, with projections reaching $2.00 for the next fiscal year .

Despite the positive outlook, key risks remain elevated . These include potential operational disruptions at the Washington Works facility, supply chain volatility stemming from geopolitical tensions, and ongoing regulatory changes . Additionally, the company maintains a negative price-to-earnings ratio of -6.38, reflecting recent earnings volatility . The payout ratio is also negative at -13.26%, due to the shift from significant losses toward projected profitability.

Chemours, established in 2015 as a spin-off from DuPont, continues to focus on performance chemicals aimed at lowering carbon footprints . The company operates through three core segments, balancing innovation with environmental stewardship . With a Zacks Rank of #1 (Strong Buy) and a positive Earnings ESP of +27.17%, the stock is positioned as a compelling candidate for an earnings surprise . The convergence of institutional buying and analyst upgrades suggests a potential inflection point for the specialty chemicals firm.